Source:http://linkedlifedata.com/resource/pubmed/id/16360359
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2005-12-19
|
| pubmed:abstractText |
Myocardial perfusion (MP) may differ in physiologic and pathologic left ventricular hypertrophy (LVH). We compared MP in LVH in elite athletes and patients with hypertension with healthy, age-matched subjects. We included 12 rowers with LVH, 19 patients with hypertension with LVH, and 2 age-matched groups of healthy subjects (n = 11 and n = 12). The left ventricular mass index was determined echocardiographically. MP was measured by N-13 ammonia positron emission tomography. The maximal perfusion and perfusion reserve were studied using dipyridamole, and endothelial function was assessed by a cold pressor test. The degree of LVH was similar in athletes and those with hypertension. Compared with controls, athletes had 20% lower baseline MP (p <0.05), a similar response to the cold pressor test, and a higher perfusion reserve (31%, p <0.05). The patients with hypertension had a 25% higher baseline MP (p <0.05), a reduced increase during the cold pressor test (12% vs 25% in controls, p <0.05), and a reduced perfusion reserve (27% lower, p <0.001). The peak global perfusion (MP x left ventricular mass index) was 62% higher in athletes (p <0.05) than in controls, but the peak global perfusion in patients with hypertension did not differ from that of controls. In conclusion, physiologic LVH in athletes is suited for a high peak workload at the cost of only a small increase in basal myocardial oxygen consumption. In contrast, LVH in the presence of hypertension is a good adaptation to the increased baseline workload with maintained maximal cardiac performance. Endothelial dysfunction may contribute to the reduced perfusion reserve seen in hypertensive LVH.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0002-9149
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
96
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1692-8
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:16360359-Adult,
pubmed-meshheading:16360359-Aged,
pubmed-meshheading:16360359-Coronary Circulation,
pubmed-meshheading:16360359-Coronary Vessels,
pubmed-meshheading:16360359-Dipyridamole,
pubmed-meshheading:16360359-Echocardiography,
pubmed-meshheading:16360359-Female,
pubmed-meshheading:16360359-Heart Ventricles,
pubmed-meshheading:16360359-Humans,
pubmed-meshheading:16360359-Hypertension,
pubmed-meshheading:16360359-Hypertrophy, Left Ventricular,
pubmed-meshheading:16360359-Infusions, Intravenous,
pubmed-meshheading:16360359-Male,
pubmed-meshheading:16360359-Middle Aged,
pubmed-meshheading:16360359-Positron-Emission Tomography,
pubmed-meshheading:16360359-Sports,
pubmed-meshheading:16360359-Vasodilation,
pubmed-meshheading:16360359-Vasodilator Agents,
pubmed-meshheading:16360359-Ventricular Function
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy.
|
| pubmed:affiliation |
Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet University Hospital, Copenhagen, Denmark. kjaer@mfi.ku.dk
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|